GlassScriptPhysician profile
Abigail Schoch
NPI 1326767765
$3,367.26
in general payments reported to CMS, 2019-2025
24 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $216 · 2023: $1,117 · 2024: $1,023 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.56 | 2022-2025 | |
| Lilly USA, LLC | $452.36 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $439.09 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $389.04 | 2022-2025 | Evenity, Prolia, Otezla |
| Radius Health, INC. | $323.93 | 2022-2025 | Tymlos |
| Pfizer INC. | $237.00 | 2023-2025 | |
| Exact Sciences Corporation | $166.16 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $135.96 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $122.18 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $91.52 | 2022-2025 | Airsupra |
| Alexion Pharmaceuticals, INC. | $65.29 | 2022-2025 | Strensiq |
| Biohaven Pharmaceutical Holding Company LTD. | $60.42 | 2022 | |
| Idorsia Pharmaceuticals US INC | $55.88 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $46.39 | 2023 | Belsomra, Steglatro, Verquvo |
| Tris Pharma INC | $33.82 | 2025 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $28.73 | 2023 | |
| Mylan Specialty L.P. | $25.29 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $22.45 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $20.08 | 2024 | Spravato |
| Dexcom, INC. | $20.07 | 2024 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $16.56 | 2024 | Crysvita |
| Axsome Therapeutics, INC. | $16.48 | 2023 | Auvelity |
| Daiichi Sankyo INC. | $15.67 | 2024 | Injectafer |
| Almatica Pharma LLC | $13.33 | 2024 | Teriparatide, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Schoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.